



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G01N 33/53, 33/543, 33/557, 33/564, C07K 16/00, C12Q 1/68		A1	(11) International Publication Number: WO 97/16727
			(43) International Publication Date: 9 May 1997 (09.05.97)
(21) International Application Number: PCT/US96/16885		(81) Designated States: AU, CA, IL, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 18 October 1996 (18.10.96)			
(30) Priority Data: 08/548,340 1 November 1995 (01.11.95) US		Published With international search report.	
(71) Applicant: BIOTRANSPLANT, INC. [US/US]; Building 96, 13th Street, Charlestown Navy Yard, Charlestown, MA 02120 (US).			
(72) Inventors: AWWAD, Michel, G.; 38 Robin Drive, Hudson, NH 03051 (US). ABRAHAM, Sonny; 30 Page Road, Weston, MA 02193 (US). WHITE-SCHARF, Mary, E.; 19 Johnson Road, Winchester, MA 01890 (US). HOPE, James, A.; 146 Prospect Street, Hingham, MA 02043 (US).			
(74) Agents: HERRON, Charles, J. et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).			
(54) Title: ASSAY BACKGROUND REDUCTION USING GLYCOPROTEINS WITH OXIDIZED CARBOHYDRATES			
(57) Abstract			
<p>Disclosed are a composition and method for determining the levels of specific immune responsiveness to a glycoprotein in an individual being treated therewith by (i) contacting a body fluid sample obtained from the individual prior to glycoprotein treatment with glycoprotein that has been modified to have an oxidized carbohydrate portion; (ii) contacting a body fluid sample obtained from the individual subsequent to glycoprotein treatment with the glycoprotein that has been modified to have an oxidized carbohydrate portion; and (iii) observing the degree of difference in the specific immune response to the oxidized glycoprotein in the pre- and post-treatment samples.</p>			
BEST AVAILABLE COPY			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**ASSAY BACKGROUND REDUCTION
USING GLYCOPROTEINS
WITH OXIDIZED CARBOHYDRATES**

Glycoproteins, particularly monoclonal antibodies of rat or mouse origin, are increasingly being used for the treatment and diagnosis of cancer, infections, and immunological diseases. When administered to the patient, an immune response is sometimes generated by patients against these antibodies. The response is defined by the difference between the reactivity of the pre- and that of the post-treatment serum or plasma with the infused antibody.

Regulatory agencies require the monitoring and quantification of human immune response to the administered glycoprotein in treated patients. However, pre-dose reactivity of human serum or plasma, in some cases, is high and may interfere with the monitoring and quantification of the specific immune response to the glycoprotein.

In most situations, and although most of the patients are naive with respect to exposure to these proteins, a pre-treatment serum reactivity with the therapeutic protein is typically detected. This reactivity can be attributed to the

presence in human serum or plasma of "natural antibodies" reactive with the antibody and in particular with the carbohydrate portion of the administered glycoprotein. Since the pretreatment serum reactivity with the glycoprotein might either conceal or augment the real immune response, reduction of this reactivity is desired.

Awwad M, Strome PG, Gilman SC, and Axelrod HR, Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector function, *Cancer Immunology Immunotherapy*, 38:23-30 (1994) examined site-specific modification of monoclonal antibody (mAB) by periodate oxidation and subsequent conjugation to either a peptide linker/chelator or a cytotoxic drug. These mAB-associated carbohydrates were also modified metabolically by incubating hybridoma cells in the presence of a glucosidase inhibitor (deoxymannojirimycin) to produce high-mannose antibody. It was concluded that modification of mAB carbohydrates did not compromise their *in vivo* or *in vitro* biological functions and that, therefore, combination therapy using immunomodulators to enhance the effector functions of site-specific immunoconjugates could be seriously contemplated.

In accordance with one aspect of the invention it has been observed that the use of oxidized glycoprotein-associated carbohydrates results in a much lower pretreatment reaction with "natural antibodies" as compared to the unmodified forms, i.e., reduces the background level of reactivity of human serum to these glycoproteins so that it is less likely to interfere with and accurate determination of pre- and post-treatment patient reactivities. Modification can be achieved chemically, enzymatically or by the use of glycosylation inhibitors in tissue cultures producing the glycoprotein, e.g., monoclonal antibody.

Alternatively, aglycosylated "glycoproteins" can be produced using molecular biology techniques.

Accordingly, the invention provides a method for determining the levels of immune responsiveness to a glycoprotein in an individual being treated therewith which comprises contacting a body fluid sample obtained from said individual prior to glycoprotein treatment with the glycoprotein that has been modified to have an oxidized carbohydrate portion;

contacting a body fluid sample obtained from said individual after glycoprotein treatment with the glycoprotein that has been modified to have an oxidized carbohydrate portion; and

observing the degree of difference in the specific binding response of the oxidized glycoprotein with the pre- and post-treatment samples. Preferably the oxidized carbohydrate portion of the modified glycoprotein is oxidized by the presence of aldehyde groups on the carbohydrate portion. It is particularly preferred that the oxidized carbohydrate portion of the modified glycoprotein has at least about three aldehyde groups.

Preferably the glycoprotein for which levels of responsiveness are being determined is an antibody, particularly a xenogeneic antibody or a monoclonal antibody. Preferably the level of responsiveness is measured by an in vitro assay of serum from said individual.

In another aspect the invention provides a composition for determining the levels of specific immune responsiveness to a glycoprotein in pre- and post- treatment samples in an individual being treated therewith which comprises:

the glycoprotein that has been modified to have an oxidized carbohydrate portion; and

means for observing the degree of difference in the specific immune response of the oxidized glycoprotein with the pre- and post- treatment samples. Preferably the composition is an *in vitro* assay composition and the oxidized carbohydrate portion of the modified glycoprotein is oxidized by the presence of aldehyde groups on the carbohydrate portion. It is particularly preferred that the oxidized carbohydrate portion of the modified glycoprotein has at least about three aldehyde groups. Preferably the glycoprotein for which levels of responsiveness are being determined is an antibody, particularly a xenogeneic antibody or a monoclonal antibody.

Conditions for the chemical as well as the enzymatic modification process vary with the level and type of glycosylation of a glycoprotein.

Figure 1 shows reactivity of different sera from healthy blood donors with rat monoclonal antibody BTI-322. Positive control is hyper-immune serum obtained from chimpanzee immunized with BTI-322 (chimp). Concentration of serum used was 0.4%.

Figures 2A-2D show the A_{280} HPLC profiles of two batches of oxidized BTI-322 (Figures 2A and 2B), and that of the unoxidized BTI-322 Reference Standard (Figure 2C) and molecular weight markers (Figure 2D). The HPLC profile of Reference Standard BTI-322 shows that $\geq 95\%$ of the preparation consisted of monomer. In addition to the monomer peak (84% or 70%), oxidized BTI-322 elution profiles showed a second peak which constituted about 13% or 27% of the sample, respectively. Probably, this peak consists of aggregated BTI-322. Based on the retention time, this fraction consists mainly of BTI-322 dimers.

Figures 3A and 3B show that aggregates detected by HPLC were also detected by SDS-PAGE under non-reducing (Figure 3B) as well as reducing (Figure 3A) conditions. Oxidized BTI-322, with the exception of an additional aggregate band, has a similar migration pattern and the same number of bands as the Reference Standard.

The development of specific binding assay techniques has provided extremely useful analytical methods for determining various substances of diagnostic, medical, environmental and industrial importance which appear in various liquid or solid (e.g., tissue) samples at very low concentrations. Specific binding assays are based on the specific interaction between a bindable analyte under determination and a binding partner therefor, i.e. analyte-specific moiety. The binding of the analyte-specific moiety and interaction of any additional reagents, if necessary, effect a mechanical separation of bound and unbound labeled analyte or affect the label in such a way as to modulate the detectable signal. The former situation is normally referred to as heterogeneous and the latter as homogeneous, in that the latter does not require a separation step.

Where either the analyte or its binding partner is a target antigen or hapten and the other is an antibody or specific binding fragment of such an antibody, the assay is known as an immunoassay.

In conventional label conjugate specific binding assay techniques, a sample of the liquid medium to be assayed is combined with various reagent compositions. Such compositions include a label conjugate comprising a binding component incorporated with a label. The binding component in the conjugate participates with other constituents, if any, of the reagent composition and the ligand in the medium

under assay to form a binding reaction system producing two species or forms of the conjugate, e.g., a bound-species (conjugate complex) and a free-species. In the bound-species, the binding component of the conjugate is bound by a corresponding binding partner whereas in the free species, the binding component is not so bound. The amount or proportion of the conjugate that results in the bound species compared to the free species is a function of the presence (or amount) of the analyte to be detected in the test sample.

An alternative format for specific binding assays is the "sandwich" assay protocol in which the target analyte is bound between a first specific binding partner, which is fixed directly or through a linkage group to a solid matrix, and a second specific binding partner, which is associated with a signal generating or labeling system.

Additional immunoassay formats and protocols are also known in the art and are applicable to use in the present invention. Various binding assays using immobilized or immobilizable materials for the direct immobilization of one of the binding participants in a binding assay reaction, e.g., immobilized antigen or antibody, in order to accomplish the desired separation of the bound and free forms of a labeled reagent, have been proposed. In particular, a number of such binding assays have been described wherein an antibody to an antigen to be detected is bound to an immobilizing material such as the inner wall of a test tube or a plastic bead.

For example, in U.S. Pat. No. 4,243,749, a competitive binding assay is disclosed wherein a reaction is carried out in a test tube having a specific antibody to a hapten under determination insolubilized or immobilized

on the inner wall of the test tube. The reaction includes a labeled hapten conjugate wherein the quantity of the labeled hapten conjugate which becomes bound to the test tube wall is inversely proportional to the amount of the hapten under determination.

Another of such binding assays is described by U.S. Pat. No. 4,230,683 which discloses a method employing a 6 mm polystyrene bead having antigen or antibody bound thereto wherein the antigen or antibody is reacted with a hapten-conjugated antibody to the antigen or antibody. The bound hapten-conjugated antibody is further reacted with labeled anti-hapten antibody in order to determine the amount of antigen or antibody in a test sample.

Still another of such binding assays is described by U.S. Pat. No. 4,228,237 which discloses a method for the detection and determination of ligands in a liquid medium using enzyme labeled avidin and a biotin labeled reagent in a specific binding process. In this method, the ligand to be detected is contacted with an insoluble phase containing a specific binding substance for the ligand.

In addition to the direct immobilization techniques heretofore described, indirect immobilization by marking or labeling a binding assay reaction participant to be immobilized with a first binding substance, and then adding an immobilized second binding substance, has been proposed.

For example, U.S. Pat. No. 4,298,685 discloses an enzyme immunoassay wherein a sample containing a biological substance under determination is mixed with antibodies to the biological substance tagged with biotin and with an enzyme-labeled form of the substance under assay. An

immobilized form of avidin is then added wherein the avidin binds to the biotin-tagged antibody to immobilize the antibody-bound fraction of the enzyme-labeled reagent. Similarly, United Kingdom Patent Application No. GB 2,084,317A discloses an antigen-linked competitive enzyme immunoassay using avidin bound to a solid material and a biotin-labeled antigen. Radiolabeled and enzyme-tagged immunoassays require some type of separation step. Recently, a different approach was disclosed which does not require a separation step and therefore has been referred to as a homogeneous system, in contrast to a heterogeneous system in which separation is essential. U.S. Pat. No. 3,817,837 discloses a competitive binding assay method involving the steps of combining the liquid to be assayed with a soluble complex consisting of an enzyme as a labeling substance covalently bound to the ligand to be detected and with a soluble receptor, usually an antibody, for the ligand; and analyzing for the effect of the liquid to be assayed on the enzymatic activity of the enzyme in the complex.

Still further, the labeled reagent can include other conventional detectable chemical group. Such detectable chemical group can be any material having a detectable physical or chemical property. Such materials have been well-developed in the field of immunoassays and in general any label useful in such methods can be applied to the present invention. Particularly useful are enzymatically active groups, such as enzymes (see Clin. Chem. (1976)22:1243), enzyme substrates (see U.S. Pat. No. 4,492,751), prosthetic groups or coenzymes (see U.S. Pat. Nos. 4,230,797 and 4,238,565), and enzyme inhibitors (see U.S. Pat. No. 4,134,792); spin labels; fluorescers (see Clin. Chem. (1979)25:353); chromophores; luminescers such as chemiluminescers and bioluminescers

(see U.S. Pat. No. 4,380,580); specifically bindable ligands (e.g., biotin and haptens); electroactive species; and radioisotopes such as ^3H , ^{35}S , ^{32}P , ^{125}I , and ^{14}C . Such labels and labeling pairs are detected on the basis of their own physical properties (e.g., fluorescers, chromophores and radioisotopes) or their reactive or binding properties (e.g., enzymes, substrates, coenzymes and inhibitors).

Example 1

Assay Background Reduction Using Monoclonal Antibodies With Oxidized Carbohydrates

BTI-322, a rat anti-human CD2 antibody, currently is being used in clinical studies.

An assay was developed to measure human anti-rat antibody response (HARA) in patients treated with BTI-322, a rat IgG_{2b} anti-CD2 antibody. However, serum harvested from patients before infusion with the antibody and from blood donors that have not been exposed previously to rat IgG showed reactivity with BTI-322. This pre-dose reactivity may interfere in the monitoring and quantification of HARA. This study was conducted to determine whether modification of antibody-carbohydrates by oxidation can facilitate monitoring and quantification of HARA by reducing the pre-dose antibody binding activity.

The term "hyper-immune animals" relates to chimpanzees that were injected and then boosted, 9 months later, with BTI-322.

The term "pre-immune serum" refers to serum harvested from animals (Chimpanzees) before infusion of BTI-322.

The term "pre-dose serum" refers to serum from patients before infusion of BTI-322 or from healthy blood donors.

Materials

Antibodies: The following antibodies were used in conjunction with the ELISA assay: BTI-322 rat monoclonal anti-human CD2 (BioTransplant, Inc.); unmodified and HRP-conjugated rabbit immunoglobulin to rat immunoglobulin (Dako); HRP-conjugated donkey anti-human IgG antibody (Accurate); mouse anti-rat IgG_{2b} antibody (Imex, MARG2b-3); and a cocktail of HRP-conjugated mouse anti-rat κ chain antibodies (Imex, MARK-1/3-PO).

Biochemicals: Oxidation was achieved by sodium m-periodate (Sigma). The efficiency of oxidation was determined by para-nitrophenyl hydrazine (pNPH, ICN) reaction (1). O-phenylenediamine Dihydrochloride (OPD, Sigma) at a concentration of 0.091 mg/mL in phosphate citrate buffer with urea hydrogen peroxide (Sigma) was used as an ELISA color development reagent. Tween 20 (Sigma) in PBS (Sigma) was used as an ELISA washing buffer and 1% BSA (Sigma) in PBS-Tween was used to block ELISA plates. Tris buffer (Sigma) was used for storage of oxidized antibody.

Methods

HARA Assay: Briefly, 96-well plates (certified Maxisorb Nunc-Immuno plates) were coated with 50 μ L of 5 μ g/mL of unmodified or oxidized BET-322. A decreasing concentration of pre- and hyper-immune chimp sera as well as human serum was loaded onto the coated plates. Bound chimp and human gamma-globulins were detected by donkey anti-human IgG. Color development was then achieved by OPD.

Oxidation: BTI-322 (Lot No. S082/S3), at a concentration of ≥ 5 mg/mL, was incubated at 770-fold molar

ratio with sodium m-periodate. The oxidized antibody was then desalted on a prepacked PD-10 gel filtration column (Pharmacia Biotech). The efficiency of oxidation was determined by measuring the number of aldehyde groups generated. This was achieved by reacting para-nitrophenylhydrazine (pNPH) with the aldehyde groups on the oxidized antibody and then determining the molar ratio of pNPH to BTI-322 by spectrophotometry at 390 nm and 280 nm, respectively, as described in Shrines RL, Fuson RC, and Curtin DY, The systemic identification of organic compounds, a laboratory manual, 5th ed. Wiley, New York, P 126 (1967). Molarity was calculated using 208000 and 8100 as the values for the molar extinction coefficients of BTI-322 and pNPH, respectively. A molecule of unmodified (native) and oxidized BTI-322 typically contained less than 1 and ≥ 3 aldehydes groups, respectively. Using an ELISA, it was shown that the reactivity of pre-treatment serum with oxidized BTI-322 was substantially reduced as compared with that of native BTI-322.

Characteristics and Stability of Oxidized BTI-322:

The biochemical stability of oxidized antibody was compared to that of the unmodified BTI-322 by comparing the HPLC (size exclusion) elution profiles and SDS-PAGE migration patterns of these antibody forms were compared. Briefly, 50 μ L of oxidized and unoxidized BTI-322 were loaded onto Water HPLC (Millipore) and eluted with PBS. The A_{280} HPLC elution profiles of the different forms of BTI-322 were compared.

The migration patterns on SDS-PAGE were produced by loading about 5 μ g of oxidized or unoxidized BTI-322 under reducing and non-reducing conditions onto 4-20% gels (BioRad). Gels were stained with Coomassie Blue and the migration patterns were then compared.

To assess the functional stability of the oxidized antibody, the reactivity of soluble CD2 as well as the anti-BTI-322 reactivity of Chimpanzee hyper-immune serum, rabbit polyclonal and mouse monoclonal antibodies with the oxidized form was compared to that of the unoxidized form.

The immunoreactivity of BTI-322, i.e., its reactivity with CD2, was assessed using plates coated with recombinant soluble human CD2 (50 μ L/well of 5 μ g/mL). These plates were loaded with a graded dose of oxidized and unoxidized BTI-322. Captured antibodies were then detected by rabbit immunoglobulin to rat immunoglobulin conjugated to HRP (DAKO). Color development was achieved using the substrate o-phenylenediamine dihydrochloride (OPD). Reactivity of the two forms of BTI-322 to rabbit polyclonal antibody was determined in an assay similar to that of immunoreactivity except that the capture antibody was unconjugated rabbit immunoglobulins to rat immunoglobulins.

Reactivity with mouse monoclonal antibodies was determined by using mouse anti-rat IgG2b (MARG2b-3, IMEX) to capture the two forms of BTI-322 and HRP-conjugated mouse monoclonal antibodies to rat κ chain to detect captured antibodies. Color development was achieved, as usual, using OPD.

Human and Chimpanzee Serum: Chimpanzee serum was collected from 2 animals 14 days after being boosted with BTI-322, approximately 9 months after the priming dose. Day 14 sera were pooled and used as positive control in every experiment on every plate. Chimpanzee serum was diluted at first 50-fold, starting concentration, followed by 7 five-fold dilutions. Dilution was achieved in PBS-Tween (0.5%).

Human serum was collected from healthy blood donors that were naive to rat immunoglobulin. In other words, these donors had no documented previous exposure to rat immunoglobulin. The reactivity of human serum with BTI-322 was assessed using HARA assay (see above).

Data analysis: ELISA data were analyzed by comparing averages of triplicates of optical density readings. HPLC data were analyzed by comparing the A_{280} elution profile of unmodified BTI-322 to that of the oxidized form. This involved comparing the proportions of monomer in the different preparations. SDS-PAGE data were analyzed by comparing the number of bands and the migration pattern of the different BTI-322 forms under reduced and non-reduced conditions.

Results

Reactivity of Human and Chimpanzee Serum with BTI-322:

Reactivity of Pre- and Hyper-Immune Chimpanzee Serum with BTI-322. Antibodies generated against BTI-322 following infusion into patients must be monitored and quantified. Since patients' sera were not available, pooled hyperimmune sera from 2 chimps that were injected with BTI-322 and then boosted about 9 months later were used as positive control. Table 1 shows the reactivity in a HARA assay of pre- and hyper-immune chimpanzee sera with BTI-322. Optical density readings obtained using hyper-serum were significantly higher than those obtained using pre-immune chimp serum. This indicates that hyper-immune serum contains anti-BTI-322 antibodies. Note that serum harvested from chimpanzees before injecting BTI-322 (pre-immune) had some reactivity with BTI-322. The addition of BTI-322 to hyperimmune chimpanzee serum reduced detectable HARA to the pre-dose level. This demonstrates the specificity of the interaction of chimpanzee serum with BTI-322.

Table 1
Reactivity of Pre- and Hyper-
Immune Chimpanzee Serum with BTI-322

Serum Concentration (%)	Hyper-Immune Chimp	Dose of BTI-322 ($\mu\text{g/mL}$)			Pre-Immune Chimp
		80.5	8.7	0.87	Pre-dose
0.4	0.715	0.379	0.544	0.639	0.203
0.08	0.642	0.305	0.35	0.547	0.297
0.016	0.495	0.135	0.203	0.251	0.285
0.0032	0.241	0.03	0.08	0.099	0.175
0.00064	0.097	0.019	0.021	0.036	0.06
0.000128	0.037	0	0.025	0.013	0.024

Reactivity of healthy donor sera with BTI-322: Similar to chimpanzee pre-immune serum, sera harvested from healthy blood donors with no documented previous exposure to rat immunoglobulin showed varied level of reactivity with BTI-322 (Figure 1).

Oxidation of BTI-322: At least three different batches of oxidized antibody were produced by incubation of BTI-322, in complete darkness, with sodium m-periodate for 1 hour. Oxidized antibody was then desalted on prepacked G-23m Sephadex columns. After two rounds of oxidation, the molar ration of pNPH to oxidized BTI-322 was 3, 4 and 10 as compared to 0.6 of un-oxidized control BTI-322. These results indicate that whereas no free aldehyde groups could

be found in un-oxidized BTI-322, 3-10 groups could be found in oxidized antibody. These results indicate that oxidation was successful.

Biochemical Stability of Oxidized BTI-322

Figures 2A-2D shows the size exclusion profiles (A_{280}) of two batches of oxidized BTI-322 (Figures 2A and 2B) and that of the Reference Standard. HPLC profile of Reference Standard (Figure 2C) shows that >95% of the same consisted of monomer. In addition to the monomer peak, oxidized BTI-322 elution profiles showed a second peak which constituted about 13% or 27%, respectively of the two preparations. Probably, this peak consists mainly of BTI-322 aggregate. Based on the retention time, this aggregate consists mainly of BTI-322 dimers.

Figure 2A shows the A_{280} Waters HPLC profile of a first batch of oxidized BTI-322, where the reported test sample analysis was as follows:

Analysis of Test Sample

#	Retention Time (min)	Height (uV)	Area (uV*sec)	% Height	% Area
1	6.350	3379.133	123771.44	10.32	13.13
2	7.350	28286.467	796564.96	86.41	84.51
3	9.200	434.333	12136.60	1.33	1.29
4	11.067	635.714	10054.91	1.94	1.07

Figure 2B shows the A_{280} Waters HPLC profile of a second batch of oxidized BTI-322, where the reported test sample analysis was as follows:

Analysis of Test Sample

#	Retention Time (min)	Height (uV)	Area (uV*sec)	% Height	% Area
1	6.383	39067.141	1801700.26	17.79	27.04
2	7.333	174910.418	4684104.09	79.64	70.29
3	9.183	1632.482	89786.63	0.74	1.35
4	11.133	2938.524	71887.16	1.34	1.08
5	11.500	1077.771	16252.91	0.49	0.24

Figure 2C shows the A₂₈₀ Waters HPLC profile of an unoxidized BTI-322, where the reported test sample analysis was as follows:

Analysis of Test Sample

#	Retention Time (min)	Height (uV)	Area (uV*sec)	% Height	% Area
1	0.783	571.989	22053.38	0.26	0.41
2	5.600	1274.850	32016.81	0.57	0.59
3	6.400	2477.362	83736.27	1.11	1.55
4	7.350	215841.157	5179856.91	96.40	95.73
5	8.983	1385.577	58815.86	0.62	1.09
6	9.833	633.184	6946.22	0.28	0.13
7	10.017	513.864	3424.26	0.23	0.06
8	10.150	493.449	12107.64	0.22	0.22
9	10.833	400.073	8396.61	0.18	0.16
10	11.317	303.320	3415.37	0.14	0.06

Figure 4D shows the A₂₈₀ Waters HPLC profile of molecular weight standards, where the reported test sample analysis was as follows:

Analysis of Test Sample

#	Retention Time (min)	Height (uV)	Area (uV*sec)	% Height	% Area
1	5.650	483553.045	21972819.63	11.00	18.56
2	6.050				
3	7.517	615030.303	29158589.10	13.99	24.63
4	8.433	658785.225	17680701.34	14.99	14.94
5	9.020				
6	9.983	1021040.037	20970629.68	23.23	17.72
7	11.167	1598440.282	28259944.11	36.37	23.87
8	11.900				
9	13.293	17794.155	325114.14	0.40	0.27

Figures 3A and 3B show the SDS-PAGE migration pattern of oxidized [Lanes 8, 7, 6 and 5], unoxidized [Lanes 3 and 4 (Reference Standard)], sample buffer (Lane 2), and molecular weight standards (Lane 1) under reducing (Figure 3A) and non-reducing (Figure 3B) conditions. Under non-reduced as well as reduced conditions, oxidized BTI-322 has an identical migration pattern and the same number of bands as the Reference Standard.

The above results indicate that oxidation did not alter significantly the biochemical characteristics of BTI-322.

Functional Stability of Oxidized BTI-322:

To test whether oxidation has affected the capacity of BTI-322 to bind CD2, a graded concentration of Reference Standard and the different batches of oxidized BTI-322 were loaded onto plates coated with recombinant soluble human CD2. Captured antibody was then detected using HRP-conjugated

rabbit anti-rat immunoglobulin. Since equivalent optical density readings (Tables 2 and 3) were observed for oxidized and un-oxidized antibody, oxidation, therefore, did not affect binding of BTI-322 to CD2.

Table 2

Reactivity of Oxidized BTI-322 (Batch 1) with CD2

BTI-322 Concentration (ng/ml)	Optical Density of BTI-322	
	Oxidized	Reference
10,000	0.483	0.397
5,000	0.5236	0.441
2,500	0.499	0.414
1,250	0.471	0.387
625	0.452	0.356
312.5	0.376	0.312
156.25	0.324	0.284
78.125	0.197	0.258
39.063	0.194	0.205
19.531	0.213	0.199
9.766	0.204	0.187
4.883	0.194	0.197
Blank	0.186	0.186

Table 3

Reactivity of Oxidized BTI-322 (Batch 2) with CD2

BTI-322 Concentration (ng/ml)	Optical Density of BTI-322	
	Oxidized	Reference
10,000	0.476	0.421
5,000	0.442	0.377
2,500	0.424	0.362
1,250	0.389	0.318
625	0.322	0.3
312.5	0.269	0.13
156.25	0.221	0.138
78.125	0.149	0.102
39.063	0.053	0.078
19.531	0.048	0.044
Blank	0.189	0.189

To test whether oxidation modified the epitopes recognized by polyclonal rabbit immunoglobulin to rat immunoglobulin, plates coated with the polyclonal antibody were loaded with graded concentrations of both forms of BTI-322. Equivalent optical density readings were obtained using both forms of BTI-322 (Table 4). This indicates that oxidation did not change the epitopes that are recognized by polyclonal rabbit anti-rat antibodies.

Table 4
Reactivity of Polyclonal Rabbit
Anti-rat Antibody with Oxidized BTI-322 (Batch 1)

BTI-322 Concentration (ng/ml)	Oxidized	Reference
10,000	0.656	0.664
5,000	0.681	0.674
2,500	0.609	0.642
1,250	0.647	0.633
625	0.661	0.658
312.5	0.607	0.637
156.25	0.594	0.649
78.125	0.49	0.562
39.06	0.389	0.361
19.53	0.305	0.234
0	0.057	0.057

The effect of oxidation of BTI-322 on specific epitopes recognized by mouse monoclonal antibodies to rat IgG_{2b} and rat κ chain was determined. MARG2b-3 (anti-rat α -2b) coated plates were loaded with oxidized and un-oxidized BTI-322 and the captured antibodies were detected by MARK-1/3-PO anti-rat κ). Results in Table 5 show that the optical density readings of the two forms of antibodies were equivalent. This indicates that oxidation did not modify epitopes recognized by mouse monoclonal antibodies.

Table 5
Reactivity of Mouse Monoclonal
Antibodies with Oxidized BTI-322

BTI-322 Concentration (ng/ml)	Reference	Oxidized
10,000	0.496	0.512
5,000	0.469	0.495
2,500	0.475	0.456
1,250	0.460	0.442
625	0.416	0.463
312.5	0.388	0.403
156.25	0.374	0.315
78.125	0.292	0.256
39.06	0.187	0.162
19.53	0.115	0.096
0	0.070	0.07

The effect of oxidation on the specific anti-BTI-322 reactivity in hyperimmune Chimpanzee serum was tested by performing a HARA assay using plates coated with either un-oxidized or oxidized BTI-322. Results in Table 6 show that optical density readings obtained using a serial dilution of hyperimmune Chimpanzee serum in both plates were equivalent. This indicates that oxidation did not have an effect on the specific anti-BTI-322 reactivity.

In addition, results in Table 6 also demonstrate that oxidation of BTI-322 can cause 5-20 fold reduction in the reactivity of BTI-322 with serum from an individual (H23) that is naive to rat gamma-globulin.

Table 6

Reactivity of Chimpanzee serum with oxidized BTI-322

Serum Concentration (1%)	Reference Standard		Oxidized		Oxidized	
	H23	Chimp	H23	Chimp	H23	Chimp
2	0.307	ND	0.179	ND	0.196	ND
0.4	0.306	ND	0.123	ND	0.135	ND
0.08	0.205	0.543	0.058	0.520	0.063	0.537
0.016	0.097	0.376	0.019	0.326	0.020	0.347
0.0032	0.037	ND	0.002	ND	0.005	ND
0	0.054	0.054	0.054	0.054	0.054	0.054

Conclusions

In summary, neither the biochemical nor the functional stability of BTI-322 were altered by oxidation. HPLC profile and SDS-PAGE migration patterns of un-oxidized and oxidized BTI-322 were equivalent. Binding of BTI-322 to its antigen (recombinant soluble human CD2) was not modified by oxidation. Binding of mono- and polyclonal antibodies to rat determinants of BTI-322 was not modified by oxidation. Binding of specific chimpanzee anti-BTI-322 antibody to BTI-322 was not modified by oxidation. Oxidation can cause a reduction of the pre-dose reactivity of human serum with BTI-322. The reactivity of the oxidized antibody with serum from healthy blood volunteers was then determined. The results demonstrate that modification of antibody-associated carbohydrates by oxidation can cause 5-20-fold reduction in the level of the pre-dose reactivity of human serum with BTI-322.

What Is Claimed Is:

1. A method for determining the levels of specific immune responsiveness to a glycoprotein in an individual being treated therewith which comprises:

contacting a body fluid sample obtained from said individual prior to glycoprotein treatment with the glycoprotein that has been modified to have an oxidized carbohydrate portion;

contacting a body fluid sample obtained from said individual subsequent to glycoprotein treatment with the glycoprotein that has been modified to have an oxidized carbohydrate portion; and

observing the degree of difference in the specific immune response to the oxidized glycoprotein in the pre- and post-treatment samples.

2. The method of claim 1 wherein the glycoprotein for which levels of responsiveness are being determined is an antibody.

3. The method of claim 2 wherein the antibody is a xenogeneic antibody.

4. The method of claim 2 wherein the antibody is a monoclonal antibody.

5. The method of claim 1 wherein the level of responsiveness is measured by an in vitro assay of serum or plasma from said individual.

6. The method of claim 1 wherein the oxidized carbohydrate portion of the modified glycoprotein is characterized by the presence of aldehyde groups on the carbohydrate portion.

7. The method of claim 6 wherein the oxidized carbohydrate portion of the modified glycoprotein has at least approximately three aldehyde groups.

8. A composition for determining the levels of specific immune responsiveness to a glycoprotein in pre- and post-treatment samples in an individual being treated therewith which comprises:

the glycoprotein that has been modified to have an oxidized carbohydrate portion; and

means for observing the degree of difference in the specific immune response to the glycoprotein and the oxidized glycoprotein in the pre- and post- treatment samples.

9. The composition of claim 8 wherein the glycoprotein for which levels of responsiveness are being determined is an antibody.

10. The composition of claim 9 wherein the antibody is a xenogeneic antibody.

11. The composition of claim 9 wherein the antibody is a monoclonal antibody.

12. The composition of claim 8 wherein the oxidized carbohydrate portion of the modified glycoprotein is characterized by the presence of aldehyde groups on the carbohydrate portion.

13. The composition of claim 12 wherein the oxidized carbohydrate portion of the modified glycoprotein has at least approximately three aldehyde groups.

FIG. 1


HARA In Serum Of Healthy Blood
Donors

FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A



FIG. 3B



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/16885

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,057,313 A (SHIH ET AL) 15 October 1991 (15.10.91),	8-13
---	see entire document, especially column 4, lines 4-11; column	-----
Y	6, line 63 - column 7, line 6; column 7, lines 21-22; Example	1-7
	3.	
X	US 4,965,069 A (QUASH ET AL) 23 October 1990	1, 5-8, 12, 13
---	(23.10.90), see entire document.	-----2-4, 9-
Y		11
X	US 4,966,999 A (COUGHLIN ET AL) 30 October 1990	8-13
	(30.10.90), see entire document, especially column 8, line	
	10 - column 10, line 45.	

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

03 DECEMBER 1996

Date of mailing of the international search report

21 JAN 1997

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CAROL A. SPIEGEL

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/16885

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4,741,900 A (ALVAREZ ET AL) 03 May 1988 (03.05.88), see entire document, especially abstract; column 5, line 48 - column 6, line 6; column 15, line 50 - column 16, line 27.	8-13
Y	US 4,867,973 A (GOERS ET AL) 19 September 1989 (19.09.89), see entire document.	1-13
Y	BUIST et al. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunology Immunotherapy. 1995, Vol. 40, No. 1, pages 24-30, see entire document.	1-13
Y	LIM et al. A flow cytometric method for the detection of the development of antibody to Orthoclone OKT3. Journal of Immunological Methods. 1989, Vol. 121, pages 197-201, see entire document.	1-13
A	US 4,671,958 A (RODWELL ET AL) 09 June 1987 (09.06.87), see entire document, especially column 13, line 44 - column 17, line 60.	1-13
A	AWWAD et al. Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions. Cancer Immunology Immunotherapy. 1994, Vol. 38, No. 1, pages 23-30, see entire document.	1-13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/16885

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6): G01N 33/53, 33/543, 33/557, 33/564; C07K 16/00; C12Q 1/68

A. CLASSIFICATION OF SUBJECT MATTER:

US CL : 435/6, 7.1, 7.5, 7.9, 7.92, 7.93, 7.94, 7.95; 436/506, 507, 517, 518; 530/390.1, 391.1, 391.5, 391.9; 424/85.91, 89

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

435/6, 7.1, 7.5, 7.9, 7.92, 7.93, 7.94, 7.95, 962, 975; 436/506, 507, 517, 518, 825; 530/390.1, 391.1, 391.5, 391.9, 806, 868; 424/85.91, 89

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ ~~FADED~~ TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.